Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Spur Therapeutics's FLT-201?
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I....
Data Insights
Risk adjusted net present value: What is the current valuation of Spur Therapeutics's FLT-201?
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I....